ArticleClinicoEconomics and outcomes research : CEOR2025
Prices of Anti-Diabetic Drugs Sold in Private Pharmacies in Côte d'Ivoire, 2023: A Secondary Analysis.
Article in ClinicoEconomics and outcomes research : CEOR, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Essential Medicines Availability, Pricing, and Stock-Outs for Hypertension and Diabetes in Private Retail Pharmacies in Zimbabwe.International journal of environmental research and public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Anti-diabetic drugs help reduce premature diabetes-related mortality. However, their prices constitute a barrier to accessing diabetes treatment. The aim of this study was to analyze the price of antidiabetic drugs sold in private pharmacies in Côte d'Ivoire. Methods: All anti-diabetic drugs listed in the Côte d'Ivoire drug registration database were selected, and wholesale prices were collected. The median price of insulins was calculated per 1000 units of active ingredient, and that of oral antidiabetics was calculated per 30 days of treatment, based on the maximum daily dose (MDD). Prices were compared with corresponding 2015 International Medical Products Price Guide by calculating the median price ratio. Results: A total of 138 drugs were identified (123 oral antidiabetics and 15 insulins and analogs). Median prices ranged from US$39.5 for rapid-acting insulins to US$245.6 for analogs (Deglutec). Median prices for oral antidiabetics ranged from US$4.5 to US$11.3 for Metformin 500mg, from US$1 (Glibenclamid 5mg) to US$27.7 (Glimepiride 1mg) for Sulfonylureas, from US$13.9 (Sitagliptin 50mg) to US$26.3 (Vidagliptin 50mg) for DDP-4 inhibitors and from US$24.2 (Empaglifozin 25mg) to US$39.4 (Empaglifozin 10mg) for SGLT-2 inhibitors. The median price ratio ranged from 7.016 (Human regular) to 38.427 (NPH70/30) for insulins group and from 2.375 (Metformin 500mg) to 26.7 (Glimepirid 4mg) for oral antidiabetics. Conclusion: Prices of antidiabetic drugs were higher than the international references prices. The development of a pricing policy emphasizing added value and price referencing, together with the development of a local generics industry, could guarantee prices that are accessible to the population and bearable by universal health coverage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.